Executive interview – Kazia Therapeutics

Published on 26 November 2019

Kazia Therapeutics has presented very encouraging initial efficacy data from the dose-ranging stage of its current Phase II trial. The data are sufficient to give Kazia confidence that it can run a large, and potentially pivotal, study starting by mid-CY20. In this video, Kazia’s CEO, Dr James Garner, explains the background to GDC-0084, which has a novel brain penetrating action which potentially could give it a unique role in the chronic treatment of glioblastoma. He discusses the latest trial data and the further development of the product in 2020.

Share this with friends and colleagues